<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901001</url>
  </required_header>
  <id_info>
    <org_study_id>Sirolimus influenza/Hui/2019</org_study_id>
    <nct_id>NCT03901001</nct_id>
  </id_info>
  <brief_title>Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza</brief_title>
  <official_title>A Randomized Controlled Trial of Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seasonal influenza epidemics are important causes of mortality and morbidity. Cytokine
      dysregulation, with high levels of pro-inflammatory cytokines, occurs in patients with severe
      influenza A(H1N1)pdm09 virus infection, A(H5N1) infection, and A(H7N9) infection. We aim to
      investigate the effects of adjunctive sirolimus in adults hospitalized with influenza A or B
      infections involving the lower respiratory tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to investigate the effects of adjunctive sirolimus in adults
      hospitalized with influenza A or B infections involving the lower respiratory tract. Patients
      will be randomized to either oseltamivir and adjunctive sirolimus or oseltamivir alone and
      assessed with reference to normalization of respiratory status (SaO2 ≥93% or respiratory rate
      ≤20/min on room air) as the primary endpoint,10 cytokines/chemokines and pro-inflammatory
      mediator changes, viral clearance, symptom resolution, ICU admission/death, day 28 mortality;
      safety profiles will also be assessed.

      The investigators hypothesize that addition of sirolimus to oseltamivir would improve
      respiratory status and other endpoints more effectively than oseltamivir alone through
      reduction of inflammatory responses without affecting viral clearance.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized trial into either oseltamivir and adjunctive sirolimus or oseltamivir alone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>normalisation of respiratory status</measure>
    <time_frame>28 days</time_frame>
    <description>SaO2 ≥93% or respiratory rate ≤20/min on room air</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>viral ribonucleic acid (RNA) in copies per milliliter</measure>
    <time_frame>28 days</time_frame>
    <description>All serially collected samples will be subjected to viral ribonucleic acid (RNA) quantification using quantitative reverse transcription PCR (qRTPCR) targeting the matrix (M)-gene ('viral load')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 in pg/ml</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin-8 in pg/ml</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 17 in pg/ml</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemokine ligand 9 (CxCL9/MIG) in pg/ml</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble tumour necrosis factor receptor-1 (sTNFR-1) in pg/ml</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 18 in pg/ml</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP in mg/L</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phospho-p38 and phospho-ERK (activated MAPKs) in mean fluorescence intensity(MFI)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phospho-inhibitor kB/IkB (NF-kB) in mean fluorescence intensity(MFI)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resolution of symptoms in days</measure>
    <time_frame>28 days</time_frame>
    <description>A standard questionnaire will be used to collect baseline and serial clinical data. These include clinical manifestations/complications, symptom severity score, vital signs (e.g. temperature, respiratory rate, oxygen saturation), fever duration, requirements for supplemental oxygen therapy and invasive/non-invasive ventilation, duration of hospitalization, death, and occurrence of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission in days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality in days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events in numbers</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>oseltamivir and adjunctive sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oseltamivir alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus and oseltamivir</intervention_name>
    <description>Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.</description>
    <arm_group_label>oseltamivir and adjunctive sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.</description>
    <arm_group_label>oseltamivir alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  influenza A and B virus infections confirmed by PCR and/or immunofluorescence assays,
             hospitalized for the management of severe manifestations of influenza, presenting
             within 5 days from illness onset, clinical evidence of lower respiratory tract
             infection (e.g. shortness of breath, tachypnea, oxygen desaturation, crepitations on
             auscultation, infiltrations or consolidations on chest radiograph) and ability to
             provide written informed consent.

        Exclusion Criteria:

          -  use of systemic corticosteroids (except for those who need low dose hydrocortisone
             50mg qid for refractory septic shock) or other immunosuppressants (e.g.
             post-chemotherapy, post-transplant, autoimmune diseases) or with known
             immuno-compromised conditions (e.g. active haematological malignancies, HIV/AIDS),
             pregnancy/lactation, end-stage renal failure/hepatic failure/cardiac failure and
             patients who have received macrolide antibiotics prior to enrolment due to their
             immuno-modulating effects. Patients on drugs that may interact and alter sirolimus
             level (rifampicin, azole antifungals, phenytoin, diltiazem, verapamil, nicardipine,
             metoclopramide, phenobarbital, carbamazepine) will be excluded for safety purposes.
             Use of investigational anti-influenza antivirals and blood products is also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David SC Hui</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanna So-Shan Ng</last_name>
    <phone>98075787</phone>
    <email>drsssng123@yahoo.com.hk</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Prof David Shu Cheong Hui</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>respiratory</keyword>
  <keyword>Mortality</keyword>
  <keyword>cytokines</keyword>
  <keyword>chemokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

